Drug intelligence / Profile preview

BB1511

Development stage: Unknown
Lead developer: Blueberry Therapeutics
Modality: Small Molecules, Drug Delivery Systems
Administration: Topical

Overview

BB1511 is a topical cream formulation developed by Blueberry Therapeutics for the treatment of atopic dermatitis. The cream is designed to support skin barrier function and reduce inflammation associated with atopic dermatitis. Its precise mechanism of action has not been defined, but it is classified as an anti-inflammatory agent. As of the latest updates, BB1511 has reached Phase I/II clinical trials for atopic dermatitis and remains in preclinical development for unspecified indications[1][3][4][7].

Beyond the preview

Go deeper on BB1511.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB1511.

Explore the full profile